AG Tschöpe have received a clinical trial grant of 350.000 euros from the DFG for the OLdTIMer study
The OLdTIMer study investigates an old and actually cheap medication (colchicine) as a treatment for inflammatory cardiomyopathy. The study has a randomized, placebo-control design and intends to treat 80 patients from 4 centers in Germany. At the end of the study we can prove/reject the concept that colchicine can in-principle be used as a treatment for non-viral inflammatory cardiomyopathy instead of corticosteroids which are frequently associated with different side effects and have many contraindications. The study aims to provide the first clinical evidence for further large-scale studies comparing colchicine to the standard of care therapies.
Colchicine has been investigated in pericarditis and in post-/COVID complications. Yet, the OLdTIMer study is very unique in the sense that it is the first human to study colchicine in cardiac muscle inflammation.
Prof. Carsten Tschöpe
Dr. Ahmed Elsanhoury
Zurück zur Übersicht